secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2021-12-30T23:59:59+00:00
Accession:  0001764013-21-000129
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant achieves FDA alignment to start Phase 3 trial for batoclimab in MG in 1H 2022
--------------------------------------------------------------------------------

- FDA Division of Neurology 1 agreed to move forward; Phase 3 for batoclimab in myasthenia gravis starts 1H 2022.
- Trial includes induction with 680mg and 340mg weekly subQ doses; primary efficacy: MG-ADL in AChR+ subjects at 12 weeks.
- Follow-on periods will explore alternative dosing (lower maintenance, higher rescue). Safety database per FDA guidance.
- Data readout expected in 2024; investor call scheduled for January 5, 2022 at 8 a.m. ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401321000129/0001764013-21-000129-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401321000129/imvt-20211230.htm
  HTML page:      https://secwatch.observer/filing/0001764013-21-000129

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer